5 Things Biotechs Should Do to Take Advantage of The Boom
Dennis Purcell (Xconomy)
A little better than placebo is still better than nothing
Adrian Dobs (Nature Medicine)
Clinical trial transparency – The road ahead
Frank David (Pharmagellan)
Pharma Blasts EMA Draft Policy on Disclosing Clinical Trial Data
Ed Silverman (Pharmalot)
Which VCs Are Poised to Profit From the Biotech IPO Boom?
Luke Timmerman (Xconomy)
Earnings calls need a shake-up. But how?
Nicole Foderaro (Brew Life)
16 Essential Biotech Twitter Follows
Adam Feuerstein (The Street)
Honored to be included on the list - and yes, I follow and second the endorsement of the entire list! You can find other recognition for BiotechDueDiligence here.
Dennis Purcell (Xconomy)
A little better than placebo is still better than nothing
Adrian Dobs (Nature Medicine)
Clinical trial transparency – The road ahead
Frank David (Pharmagellan)
Pharma Blasts EMA Draft Policy on Disclosing Clinical Trial Data
Ed Silverman (Pharmalot)
Which VCs Are Poised to Profit From the Biotech IPO Boom?
Luke Timmerman (Xconomy)
Earnings calls need a shake-up. But how?
Nicole Foderaro (Brew Life)
16 Essential Biotech Twitter Follows
Adam Feuerstein (The Street)
Honored to be included on the list - and yes, I follow and second the endorsement of the entire list! You can find other recognition for BiotechDueDiligence here.
RSS Feed
